Cognition Therapeutics presents data at AAIC on CT1812 in dementia

Cognition Therapeutics (CGTX) presented results from the Phase 2 COG1201 SHIMMER study of zervimesine, CT1812, in dementia with Lewy bodies at the Alzheimer’s Association International Conference, AAIC 2025. As previously reported, the SHIMMER study met its primary endpoint of safety and tolerability. Results showed that zervimesine treatment had a positive impact across neuropsychiatric, cognitive, motor, and functional scales. After six months of treatment, DLB patients treated with zervimesine scored an average of 86% better than placebo-treated patients on the neuropsychiatric inventory. Results from the Phase 2 COG0201 ‘SHINE’ study of zervimesine in Alzheimer’s disease were also presented at AAIC. The SHINE study met its primary endpoint of safety and tolerability. An analysis was conducted on a subgroup of participants whose Alzheimer’s disease brain pathology was less pronounced, as determined by lower levels of a protein called p-tau217 in their blood. SHINE participants with lower p-tau217 had a more robust response to zervimesine compared to those with higher p-tau217 levels regardless of their MMSE scores. Zervimesine was shown to arrest further cognitive deterioration in people with mild or moderate Alzheimer’s disease by 129% and 91%, respectively